Wednesday 16 September 2026

One To Watch

Zenas BioPharma

A global biopharma company developing and commercializing immune-based therapies.

Company Overview

Want to Update your Company's Profile?


Latest Zenas BioPharma News

UCB and Biogen build steroid-sparing case for lupus drug
4 June 2026
Zenas BioPharma tanks on Phase III obexelimab trial results
5 January 2026
Zenas inks license agreement with InnoCare for 3 autoimmune programs
8 October 2025
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024
More Zenas BioPharma news >


Today's issue

Vivan and Ad Atomica pair tumor genotype data with AI drug design
Biotechnology
Vivan and Ad Atomica pair tumor genotype data with AI drug design
16 September 2026
Pharmaceutical
ICER releases evidence report on treatment for Parkinson’s disease
16 September 2026
Pharmaceutical
Remepy welcomes new CMO to advance hybrid drug pipeline
16 September 2026
Pharmaceutical
Sling Therapeutics announces $123M financing
16 September 2026
Pharmaceutical
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
16 September 2026
Pharmaceutical
FDA unveils expedited IND pilot, begins accepting applications
16 September 2026
Biotechnology
Lundbeck wins Japanese approval for Vyepti
16 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze